公开(公告)号：US20250002855A1

公开(公告)日：2025-01-02

申请号：US18886331

申请日：2024-09-16

Applicant: Immatics US, Inc.

Inventor： Melinda MATA ,  Mamta KALRA ,  Ali MOHAMED ,  Steffen WALTER ,  Yannick BULLIARD

IPC: C12N5/0783 ,  A61K39/00 ,  C07K14/725

Abstract: An in vitro method of expanding γδ T cells includes isolating γδ T cells from a blood sample of a human subject, activating the isolated γδ T cells in the presence of an aminobisphosphonate and/or a feeder cell and at least one cytokine, expanding the activated γδ T cells, and optionally restimulating the expanded γδ T cells.

公开(公告)号：US20210285011A1

公开(公告)日：2021-09-16

申请号：US17197927

申请日：2021-03-10

Applicant: Immatics US, Inc.

Inventor： Melinda MATA ,  Mamta KALRA ,  Yannick BULLIARD ,  Steffen WALTER ,  Ali MOHAMED

IPC: C12N15/86 ,  C12N15/10 ,  C07K14/725 ,  C12N15/113

Abstract: The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.

公开(公告)号：US20250034588A1

公开(公告)日：2025-01-30

申请号：US18897063

申请日：2024-09-26

Applicant: Immatics US, Inc.

Inventor： Mamta KALRA ,  Agathe BOURGOGNE ,  Ali MOHAMED ,  Steffen WALTER

IPC: C12N15/85 ,  A61K39/00 ,  A61P35/00 ,  C12N5/10 ,  C12N7/00 ,  C12N15/86

Abstract: The present disclosure relates to T cells transduced with a viral vector at a volumetric concentration for immunotherapy and methods thereof. In another aspect, the present disclosure relates to the assessment of optimal lentiviral vector concentrations for transducing T cells. The present disclosure further provides for T cell populations produced by methods described herein.

公开(公告)号：US20230192886A1

公开(公告)日：2023-06-22

申请号：US18053705

申请日：2022-11-08

Applicant: Immatics Biotechnologies GmbH ,  Immatics US, Inc.

Inventor： Harpreet SINGH ,  Toni WEINSCHENK ,  Steffen WALTER

IPC: C07K16/30 ,  A61K38/17 ,  A61P35/00

CPC classification number: C07K16/3053 ,  A61K38/1774 ,  A61P35/00

Abstract: A method of treating a patient who has a recurrent cancer that presents a peptide, including administering to the patient a treatment composition comprising an antigen binding molecule that binds to the peptide, in which the patient has received a prior treatment with a pretreatment composition comprising a second antigen binding molecule that binds to a different peptide.

公开(公告)号：US20240115609A1

公开(公告)日：2024-04-11

申请号：US18319677

申请日：2023-05-18

Applicant: IMMATICS US, INC.

Inventor： Monique DAO ,  Steffen WALTER ,  Melinda MATA ,  Aleksandra NORWICKA ,  Yannick BULLIARD ,  Sarah MISSELL ,  Sabrina KUTTRUFF-COQUI ,  Norbert HILF

IPC: A61K35/17 ,  A61K31/663 ,  A61K31/675 ,  A61K38/20 ,  C07K14/54 ,  C07K14/55 ,  C12N5/00 ,  C12N5/0783 ,  C12N15/62 ,  C12N15/85

CPC classification number: A61K35/17 ,  A61K31/663 ,  A61K31/675 ,  A61K38/2013 ,  C07K14/5443 ,  C07K14/55 ,  C12N5/0018 ,  C12N5/0636 ,  C12N5/0638 ,  C12N15/62 ,  C12N15/8509 ,  A61K2035/122 ,  C12N2501/155 ,  C12N2501/2302 ,  C12N2501/2315 ,  C12N2501/515 ,  C12N2501/998 ,  C12N2740/10043

Abstract: The present disclosure relates to expansion and activation of T cells. In an aspect, the present disclosure relates to expansion and activation of γδ T cells that may be used for transgene expression. In another aspect, the disclosure relates to expansion and activation of γδ T cells while depleting α- and/or β-TCR positive cells. T cell populations comprising expanded γδ T cell and depleted or reduced α- and/or β-TCR positive cells are also provided for by the instant disclosure. The disclosure further provides for methods of using the disclosed T cell populations.

公开(公告)号：US20220056411A1

公开(公告)日：2022-02-24

申请号：US17409504

申请日：2021-08-23

Applicant: Immatics US, Inc.

Inventor： Mamta KALRA ,  Gagan BAJWA ,  Thomas LUCAS ,  Ali MOHAMED ,  Steffen WALTER

IPC: C12N5/0783 ,  C12N15/85 ,  C07K14/725

Abstract: A method of producing an engineered T cell population includes obtaining a cell population comprising a CD8+ T cell, isolating the CD8+ T cell from the obtained cell population, activating the isolated CD8+ T cell, introducing a nucleic acid encoding a T cell receptor (TCR) binding to an antigen in a complex with an MHC molecule into the activated CD8+ T cell, and expanding the introduced CD8+ T cell to obtain the engineered T cell population.

公开(公告)号：US20190247433A1

公开(公告)日：2019-08-15

申请号：US16271393

申请日：2019-02-08

Applicant: Immatics US, Inc.

Inventor： Mamta KALRA ,  Zoe COUGHLIN ,  Amir ALPERT ,  Steffen WALTER ,  Ali MOHAMED ,  Agathe BOURGOGNE

IPC: A61K35/17 ,  C12N5/0783 ,  C07K16/28 ,  C12N15/86 ,  A61P35/00 ,  A61P31/00

CPC classification number: A61K35/17 ,  A61P31/00 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2818 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0638 ,  C12N15/86 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2312 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2510/00

Abstract: The disclosure relates to methods of manufacturing T cells for adoptive immunotherapy. The disclosure further provides for methods of genetically transducing T cells, methods of using T cells, and T cell populations thereof. In an aspect, the disclosure provides for methods of thawing frozen peripheral blood mononuclear cells (PBMC), resting the thawed PBMC, activating the T cell in the cultured PBMC with an anti-CD3 antibody and an anti-CD28 antibody immobilized on a solid phase, transducing the activated T cell with a viral vector, expanding the transduced T cell, and obtaining expanded T cells.

公开(公告)号：US20250075230A1

公开(公告)日：2025-03-06

申请号：US18824203

申请日：2024-09-04

Applicant: Immatics US, Inc.

Inventor： Melinda MATA ,  Mamta KALRA ,  Yannick BULLIARD ,  Steffen WALTER ,  Ali MOHAMED

IPC: C12N15/86 ,  A61K39/00 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/10 ,  C12N15/113

Abstract: The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.

公开(公告)号：US20240358831A1

公开(公告)日：2024-10-31

申请号：US18685736

申请日：2022-08-24

Applicant: IMMATICS US, INC. ,  Immatics Biotechnologies GmbH

Inventor： Stefanie SPALT ,  Claudia WAGNER ,  Dominik MAURER ,  Heiko SCHUSTER ,  Steffen WALTER

IPC: A61K39/00 ,  C07K14/74 ,  C12N5/0783

CPC classification number: A61K39/4632 ,  A61K39/4611 ,  C07K14/70539 ,  C12N5/0636 ,  C12N2502/11

Abstract: The present invention relates to a method for selecting an immune cell expressing on its surface an antigen-binding protein specifically binding to a complex of a peptide A (PA) and a Major Histocompatibility Complex (MHC) molecule, comprising the steps of (i) providing a plurality of immune cells expressing different antigen-binding proteins; (ii) contacting the plurality of immune cells with a first composition comprising a complex 1A, comprising a MHC molecule 1 (M1) and a peptide A (PA), and a complex 1X, comprising M1 and a peptide B (PB); (iii) contacting the plurality of immune cells with a second composition comprising a complex 2A, comprising a MHC molecule 2 (M2) and PA, and a complex 2X, comprising M2 and a peptide C (PC); (iv) selecting from the plurality of immune cells a cell expressing an antigen binding protein that specifically binds to complex 1A, wherein complexes 1X and 2X, but not 1A and 2A, dissociate upon stimulation with a defined chemical or physical stimulus; and wherein the amino acid sequences of PB and PC differ in at least one amino acid. The invention further relates to an immune cell selected by the method according to the invention, a method of treatment using said immune cell, a kit for selecting a cell expressing on its surface an antigen-binding protein, and a peptide suitable for use in the method according to the invention.

公开(公告)号：US20240150790A1

公开(公告)日：2024-05-09

申请号：US18501269

申请日：2023-11-03

Applicant: Immatics US, Inc.

Inventor： Melinda MATA ,  Mamta KALRA ,  Yannick BULLIARD ,  Steffen WALTER ,  Ali MOHAMED

IPC: C12N15/86 ,  C07K14/725 ,  C12N15/10 ,  C12N15/113

CPC classification number: C12N15/86 ,  C07K14/7051 ,  C12N15/102 ,  C12N15/113 ,  C12N2830/48

Abstract: The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.